Understand the source comparison
Peptides for Lyme Disease: Research Comparison
Thymosin Alpha-1 Treg restoration, IL-6/TNF-alpha reduction 1.6 mg SC twice weekly × 8–12 weeks Phase III trial data in viral/autoimmune conditions; no Lyme-specific RCTs Strongest mechanistic rationale for immune recalibration in PTLDS. Addresses cytokine dys
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- Treg restoration, IL-6/TNF-alpha reduction
- 1.6 mg SC twice weekly × 8–12 weeks
- Phase III trial data in viral/autoimmune conditions; no Lyme-specific RCTs
- Strongest mechanistic rationale for immune recalibration in PTLDS. Addresses cytokine dysregulation directly
- BPC-157
- Gut barrier repair, VEGF upregulation, endotoxin reduction
- 200–500 mcg SC daily × 4–8 weeks
- Preclinical and observational human data; no controlled Lyme trials
- Addresses systemic inflammation secondary to gut permeability. Essential if GI symptoms present
- LL-37 (Cathelicidin)
- Biofilm disruption, direct Borrelia killing, dendritic cell modulation
- 200–500 mcg SC daily × 8–12 weeks
- In vitro Borrelia activity confirmed; limited human dosing data
- Most relevant for persister-form infections; requires combination with biofilm agents
- Cerebrolysin
- BDNF promotion, neuroprotection, synaptic support
- 10–30 mL IV daily × 10–20 days
- Phase III data in stroke/TBI; no Lyme-specific studies
- Strongest evidence for cognitive/neurological symptoms. High cost limits accessibility
- Dihexa
- HGF/Met pathway activation, synaptogenesis
- 5–10 mg/kg (preclinical)
- Preclinical only; human dosing not established
- Promising for cognitive recovery but insufficient safety data for clinical use
- Semax
- Microglial suppression, hippocampal neurogenesis
- 600 mcg intranasal 3× daily
- Phase II data in MCI; no Lyme trials
- Accessible nasal route and low side effect profile; worth considering for brain fog